cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30304444
title: Temporal trends and machine learning prediction for chronic kidney disease due to hypertension in young adults from 1990 to 2021: an analysis of the global burden of disease study 2021

description: Young adults aged 25–49, at the peak of work and family responsibilities, face serious health and productivity challenges when affected by chronic kidney disease (CKD) due to hypertension. Using Global Burden of Disease (GBD) 1990-2021 data, we assessed global, regional, and national CKD burden due to hypertension in young adults, focusing on mortality and disability-adjusted life years (DALYs). Trends analyzed by Joinpoint regression and forecasted to 2040 using eight machine learning models. In 2021, global mortality from CKD due to hypertension reached 18,675.24 cases, a 157.55% increase since 1990. The age-standardized mortality rate (ASMR) rose from 0.31 to 0.45 per 100,000 persons, with an average annual percentage change (AAPC) of 1.24% (<i>p</i> &lt; 0.05). DALYs increased by 145.84% to 1,122,316.38 person-years. The age-standardized disability rate (ASDR) grew from 19.39 to 27.37 per 100,000 persons, with an AAPC of 1.12% (<i>p</i> &lt; 0.05). The greatest increase occurred in the 25-29 age group, while those aged 45-49 had the highest burden. Most of the CKD burden due to hypertension was in the three lowest SDI quintiles, while high SDI regions saw the greatest increase. The Prophet model was optimal in predicting the ASMR index, while the Autoregressive Integrated Moving Average (ARIMA) model performed best for the ASDR, with projections indicating an increase in both indices by 2040. CKD due to hypertension is a growing global challenge in young adults. Substantial heterogeneity exists in the disease burden and its temporal trends across countries and regions, highlighting the strong distributive inequities of CKD worldwide.
DOI: 10.6084/m9.figshare.30304444.v1
title: Temporal trends and machine learning prediction for chronic kidney disease due to hypertension in young adults from 1990 to 2021: an analysis of the global burden of disease study 2021

description: Young adults aged 25–49, at the peak of work and family responsibilities, face serious health and productivity challenges when affected by chronic kidney disease (CKD) due to hypertension. Using Global Burden of Disease (GBD) 1990-2021 data, we assessed global, regional, and national CKD burden due to hypertension in young adults, focusing on mortality and disability-adjusted life years (DALYs). Trends analyzed by Joinpoint regression and forecasted to 2040 using eight machine learning models. In 2021, global mortality from CKD due to hypertension reached 18,675.24 cases, a 157.55% increase since 1990. The age-standardized mortality rate (ASMR) rose from 0.31 to 0.45 per 100,000 persons, with an average annual percentage change (AAPC) of 1.24% (<i>p</i> &lt; 0.05). DALYs increased by 145.84% to 1,122,316.38 person-years. The age-standardized disability rate (ASDR) grew from 19.39 to 27.37 per 100,000 persons, with an AAPC of 1.12% (<i>p</i> &lt; 0.05). The greatest increase occurred in the 25-29 age group, while those aged 45-49 had the highest burden. Most of the CKD burden due to hypertension was in the three lowest SDI quintiles, while high SDI regions saw the greatest increase. The Prophet model was optimal in predicting the ASMR index, while the Autoregressive Integrated Moving Average (ARIMA) model performed best for the ASDR, with projections indicating an increase in both indices by 2040. CKD due to hypertension is a growing global challenge in young adults. Substantial heterogeneity exists in the disease burden and its temporal trends across countries and regions, highlighting the strong distributive inequities of CKD worldwide.
DOI: 10.6084/m9.figshare.28939076
title: Effects of using app-based interventions on quality of life among breast cancer patients: a systematic review with meta-analysis

description: Application-based interventions have gradually emerged as potential tools for improving the health status of cancer patients. However, the conclusions of existing studies on the effectiveness of app-based intervention in managing breast cancer symptoms vary. This study systematically searched the PubMed, Web of Science, Scopus, Cochrane Library, and EMBASE databases from the inception of each database to October 25, 2024. Two researchers independently screened studies, extracted data, and evaluated the quality using the Cochrane Risk of Bias Tool. Data analysis was performed using RevMan 5.3 software, and the effect size was expressed as the standardized mean difference (SMD). Of 16 included randomized controlled trials, meta-analysis results indicated that, compared to usual care, app-based interventions significantly improved breast cancer patients’ quality of life (14 studies, SMD = 0.84, 95%CI = 0.48 − 1.19, <i>p</i> &lt; 0.00005, I<sup>2</sup> = 90%, GRADE = low), and positively alleviated physical pain and anxiety (5 studies, SMD = − 0.60, 95%CI = −0.92 to −0.29, <i>p</i> = 0.0002, I<sup>2</sup>= 56%, GRADE = very low; 3 studies, SMD = −0.75, 95% CI = −1.40 to −0.09, <i>p</i> = 0.03, I<sup>2</sup>= 86%, GRADE = very low). However, no statistically significant differences were observed in improving fatigue (3 studies, SMD = 0.18, 95%CI = − 0.05 − 0.42, <i>p</i> = 0.13, I<sup>2</sup> = 0%) and depression (2 studies, SMD = −0.65, 95%CI = − 2.12 − 0.82, <i>p</i> = 0.38, I<sup>2</sup> = 96%). Application-based interventions can significantly improve the quality of life of breast cancer patients, effectively relieve pain, and reduce anxiety.
DOI: 10.6084/m9.figshare.28939076.v1
title: Effects of using app-based interventions on quality of life among breast cancer patients: a systematic review with meta-analysis

description: Application-based interventions have gradually emerged as potential tools for improving the health status of cancer patients. However, the conclusions of existing studies on the effectiveness of app-based intervention in managing breast cancer symptoms vary. This study systematically searched the PubMed, Web of Science, Scopus, Cochrane Library, and EMBASE databases from the inception of each database to October 25, 2024. Two researchers independently screened studies, extracted data, and evaluated the quality using the Cochrane Risk of Bias Tool. Data analysis was performed using RevMan 5.3 software, and the effect size was expressed as the standardized mean difference (SMD). Of 16 included randomized controlled trials, meta-analysis results indicated that, compared to usual care, app-based interventions significantly improved breast cancer patients’ quality of life (14 studies, SMD = 0.84, 95%CI = 0.48 − 1.19, <i>p</i> &lt; 0.00005, I<sup>2</sup> = 90%, GRADE = low), and positively alleviated physical pain and anxiety (5 studies, SMD = − 0.60, 95%CI = −0.92 to −0.29, <i>p</i> = 0.0002, I<sup>2</sup>= 56%, GRADE = very low; 3 studies, SMD = −0.75, 95% CI = −1.40 to −0.09, <i>p</i> = 0.03, I<sup>2</sup>= 86%, GRADE = very low). However, no statistically significant differences were observed in improving fatigue (3 studies, SMD = 0.18, 95%CI = − 0.05 − 0.42, <i>p</i> = 0.13, I<sup>2</sup> = 0%) and depression (2 studies, SMD = −0.65, 95%CI = − 2.12 − 0.82, <i>p</i> = 0.38, I<sup>2</sup> = 96%). Application-based interventions can significantly improve the quality of life of breast cancer patients, effectively relieve pain, and reduce anxiety.
DOI: 10.6084/m9.figshare.30693732
title: Bronchoscopic management of airway fistulas: a clinical analysis of 45 cases with integrated bioinformatic analysis

description: Airway fistula represents a complex clinical condition where the optimal bronchoscopic management remains controversial. This study aims to evaluate clinical characteristics, bronchoscopic treatment efficacy, and prognostic factors. This retrospective study analysed 45 patients with fistulas who underwent a total of 56 bronchoscopic intervention sessions over the past seven years. The fistulas were categorized and analysed based on their size, clinical features and treatment efficacy, with prognostic factors for healing being evaluated. In parallel, a bioinformatic analysis was initiated with 2075 genes sourced from GeneCards. Following filtration, the top 20 hub genes were identified and subsequently subjected to pathway enrichment analysis to elucidate the underlying mechanisms. Compared to the non-remission group, the remission group exhibited significantly smaller fistula diameters, higher lymphocyte counts, and lower high-sensitivity C-reactive protein (hsCRP) levels. Prognostic analysis revealed that fistula size and hsCRP level were independent predictors. Small fistulas (≤5 mm) cases solely underwent blocking agent intervention had a significantly higher remission rate. While the others (&gt;5 mm) were mostly managed with stents, endobronchial valves, and cardiac occluders. Bioinformatic analysis of public data identified significant enrichment in the PI3K-AKT signaling pathway and cytokine-cytokine receptor interaction pathway, pinpointing six core genes, including CXCL8, IL1B, IL6, TNF, TGFB1, and IL13. Prioritize bronchoscopic treatment with inflammation control for small fistulas; recommend combined therapies for large fistulas.The PI3K-AKT and cytokine pathways may be involved in healing and represent potential targets for future drug development. Prioritize bronchoscopic treatment with inflammation control for small fistulas; recommend combined therapies for large fistulas. The PI3K-AKT and cytokine pathways may be involved in healing and represent potential targets for future drug development.
DOI: 10.6084/m9.figshare.30693732.v1
title: Bronchoscopic management of airway fistulas: a clinical analysis of 45 cases with integrated bioinformatic analysis

description: Airway fistula represents a complex clinical condition where the optimal bronchoscopic management remains controversial. This study aims to evaluate clinical characteristics, bronchoscopic treatment efficacy, and prognostic factors. This retrospective study analysed 45 patients with fistulas who underwent a total of 56 bronchoscopic intervention sessions over the past seven years. The fistulas were categorized and analysed based on their size, clinical features and treatment efficacy, with prognostic factors for healing being evaluated. In parallel, a bioinformatic analysis was initiated with 2075 genes sourced from GeneCards. Following filtration, the top 20 hub genes were identified and subsequently subjected to pathway enrichment analysis to elucidate the underlying mechanisms. Compared to the non-remission group, the remission group exhibited significantly smaller fistula diameters, higher lymphocyte counts, and lower high-sensitivity C-reactive protein (hsCRP) levels. Prognostic analysis revealed that fistula size and hsCRP level were independent predictors. Small fistulas (≤5 mm) cases solely underwent blocking agent intervention had a significantly higher remission rate. While the others (&gt;5 mm) were mostly managed with stents, endobronchial valves, and cardiac occluders. Bioinformatic analysis of public data identified significant enrichment in the PI3K-AKT signaling pathway and cytokine-cytokine receptor interaction pathway, pinpointing six core genes, including CXCL8, IL1B, IL6, TNF, TGFB1, and IL13. Prioritize bronchoscopic treatment with inflammation control for small fistulas; recommend combined therapies for large fistulas.The PI3K-AKT and cytokine pathways may be involved in healing and represent potential targets for future drug development. Prioritize bronchoscopic treatment with inflammation control for small fistulas; recommend combined therapies for large fistulas. The PI3K-AKT and cytokine pathways may be involved in healing and represent potential targets for future drug development.
DOI: 10.6084/m9.figshare.30083698
title: Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

description: Although some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(−) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights. A literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov focusing on studies published before 2022. The meta-analysis followed PRISMA guidelines and used RevMan 5.3 to conduct the analysis. Eleven clinical trials published between 2015 and 2022 were included in our meta-analysis, with a total of 5572 eligible patients. This meta-analysis found that HR(+)/HER2(−) metastatic breast cancer treated with CDK4/6 inhibitors plus endocrine therapy can significantly improve progression-free survival(PFS) (HR: 0.55; <i>p</i> &lt; 0.001), overall survival (OS) (HR: 0.79; <i>p</i> &lt; 0.001), objective response rate (RR = 1.50; <i>p</i> &lt; 0.001), clinical benefit rate (RR = 1.18; <i>p</i> &lt; 0.001) and decrease progressive disease rate (RR = 0.49; <i>p</i> &lt; 0.001). Clinicians need to be aware of hematological toxicities, abnormal liver function, and venous thromboembolism in the use of CDK4/6 inhibitors. Furthermore, the combination regimen also showed longer PFS in subgroup analysis. However, Asians, the number of metastasis sites, and patients using letrozole subgroups did not demonstrate differences in OS between the combination regimen and endocrine therapy alone. This meta-analysis highlights the improvement of PFS, OS, ORR, and CBR in HR(+)/HER2(−) metastatic breast cancer for CDK4/6 inhibitors, with manageable and reversible toxicities. Clinicians should be aware of hematological toxicities, liver function abnormalities, and venous thromboembolism when using CDK4/6 inhibitors. These findings make CDK4/6 inhibitors a pivotal treatment option. CDK4/6 inhibitor combined with endocrine therapy can prolong progression-free survival, overall survival, objective response rate, and clinical benefit rate, and decrease progressive disease rate. Hematological toxicities are the main concern for CDK4/6 inhibitors. Clinicians still need to be aware of adverse events such as abnormal liver function and venous thromboembolism. CDK4/6 inhibitors plus endocrine therapy improved PFS in all subgroups, but no difference in OS was observed in Asians, the number of metastasis sites, and patients using letrozole compared to endocrine therapy alone. CDK4/6 inhibitors plus endocrine therapy is a pivotal treatment option for HR(+)/HER2(−) breast cancer based on their efficacy and safety.
DOI: 10.6084/m9.figshare.30083698.v1
title: Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

description: Although some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(−) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights. A literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov focusing on studies published before 2022. The meta-analysis followed PRISMA guidelines and used RevMan 5.3 to conduct the analysis. Eleven clinical trials published between 2015 and 2022 were included in our meta-analysis, with a total of 5572 eligible patients. This meta-analysis found that HR(+)/HER2(−) metastatic breast cancer treated with CDK4/6 inhibitors plus endocrine therapy can significantly improve progression-free survival(PFS) (HR: 0.55; <i>p</i> &lt; 0.001), overall survival (OS) (HR: 0.79; <i>p</i> &lt; 0.001), objective response rate (RR = 1.50; <i>p</i> &lt; 0.001), clinical benefit rate (RR = 1.18; <i>p</i> &lt; 0.001) and decrease progressive disease rate (RR = 0.49; <i>p</i> &lt; 0.001). Clinicians need to be aware of hematological toxicities, abnormal liver function, and venous thromboembolism in the use of CDK4/6 inhibitors. Furthermore, the combination regimen also showed longer PFS in subgroup analysis. However, Asians, the number of metastasis sites, and patients using letrozole subgroups did not demonstrate differences in OS between the combination regimen and endocrine therapy alone. This meta-analysis highlights the improvement of PFS, OS, ORR, and CBR in HR(+)/HER2(−) metastatic breast cancer for CDK4/6 inhibitors, with manageable and reversible toxicities. Clinicians should be aware of hematological toxicities, liver function abnormalities, and venous thromboembolism when using CDK4/6 inhibitors. These findings make CDK4/6 inhibitors a pivotal treatment option. CDK4/6 inhibitor combined with endocrine therapy can prolong progression-free survival, overall survival, objective response rate, and clinical benefit rate, and decrease progressive disease rate. Hematological toxicities are the main concern for CDK4/6 inhibitors. Clinicians still need to be aware of adverse events such as abnormal liver function and venous thromboembolism. CDK4/6 inhibitors plus endocrine therapy improved PFS in all subgroups, but no difference in OS was observed in Asians, the number of metastasis sites, and patients using letrozole compared to endocrine therapy alone. CDK4/6 inhibitors plus endocrine therapy is a pivotal treatment option for HR(+)/HER2(−) breast cancer based on their efficacy and safety.
DOI: 10.6084/m9.figshare.30635858.v1
title: Operative versus nonoperative management of acute Achilles tendon rupture: a systematic review and meta-analysis of clinical outcomes from randomized controlled trials

description: The objective of this study was to compare the differences in re-rupture rates, complications, and functional assessments of Achilles tendon ruptures (ATRs) treated operatively or nonoperatively to guide clinical treatment choices. A literature search was performed in the PubMed, Cochrane Library, and Embase databases up to March 1, 2025, for randomized controlled trials (RCTs) involving patients with ATR receiving operative and nonoperative therapies. Primary outcomes included re-rupture rates, complications, and functional assessment. Meta-analysis of the extracted data was carried out using Review Manager 5.3 and Stata 17.0. A total of 14 RCTs were included in the meta-analysis, comprising 1,628 participants. The meta-analysis results revealed a considerably lower re-rupture rate in both the minimally invasive (MI) group (risk ratio [RR], 0.28; 95% confidence interval [CI]: 0.11 to 0.74) and the open group (RR, 0.30; 95% CI: 0.19 to 0.50). For complications, subgroup analysis showed no significant difference between the MI and nonoperative groups (RR, 2.40; 95% CI: 0.52 to 10.98), whereas the open group had a higher complication rate (RR, 3.03; 95% CI: 1.75 to 5.26) than nonoperative groups. There was no significant difference in the functional assessment between operative and nonoperative groups. Regarding return to work, the MI group returned to work earlier compared to the nonoperative group. Open operative treatment significantly reduces the rate of re-rupture compared to nonoperative treatment but is accompanied by a higher risk of complications. MI treatment offers both of these advantages, along with superiority in return to work.
DOI: 10.6084/m9.figshare.29278693
title: Take charge after long COVID: a mixed methods randomised controlled pilot study protocol

description: Post COVID-19 condition is a debilitating illness with over 200 symptoms across 10 organ systems and is presently impacting millions worldwide. The National Institute for Health and Care Excellence recommends a multidisciplinary treatment approach including person-centred self-management strategies, however evidence for specific programs is lacking. The Take Charge intervention is a person-centred, self-management rehabilitation approach that has been effective in recovery after stroke, but not yet tested in post COVID-19 condition. A prospective, single-centre, parallel, 2 group, mixed methods, randomized controlled trial with embedded process evaluation of the Take Charge intervention in individuals living with post COVID-19 condition. Participants will be at least 18 years of age, have a confirmed diagnosis of post COVID-19 condition with ongoing symptoms, and be known to a hospital clinic for assessment and treatment of patients with post-acute sequelae of COVID-19. The primary outcomes are the Modified COVID-19 Yorkshire Rehabilitation Scale and the COVID-19 Core Outcome Measure for Recovery. The secondary outcomes include physical and self-report measures, and feasibility measures. Qualitative interviews will also be conducted to understand the clinicians’ and participants’ experiences. Statistical analysis will be performed on an intention-to-treat basis using a multivariate mixed-effect linear regression model. This study adheres to the Declaration of Helsinki. This study was approved by the Southern Adelaide Clinical Human Research Ethics Committee (approval number: 2022/SSA00695/OFR: 219.22, protocol version 3.3 19 February 2024). The results will be disseminated in peer-reviewed journals, conference presentations, and media.
DOI: 10.6084/m9.figshare.29278693.v1
title: Take charge after long COVID: a mixed methods randomised controlled pilot study protocol

description: Post COVID-19 condition is a debilitating illness with over 200 symptoms across 10 organ systems and is presently impacting millions worldwide. The National Institute for Health and Care Excellence recommends a multidisciplinary treatment approach including person-centred self-management strategies, however evidence for specific programs is lacking. The Take Charge intervention is a person-centred, self-management rehabilitation approach that has been effective in recovery after stroke, but not yet tested in post COVID-19 condition. A prospective, single-centre, parallel, 2 group, mixed methods, randomized controlled trial with embedded process evaluation of the Take Charge intervention in individuals living with post COVID-19 condition. Participants will be at least 18 years of age, have a confirmed diagnosis of post COVID-19 condition with ongoing symptoms, and be known to a hospital clinic for assessment and treatment of patients with post-acute sequelae of COVID-19. The primary outcomes are the Modified COVID-19 Yorkshire Rehabilitation Scale and the COVID-19 Core Outcome Measure for Recovery. The secondary outcomes include physical and self-report measures, and feasibility measures. Qualitative interviews will also be conducted to understand the clinicians’ and participants’ experiences. Statistical analysis will be performed on an intention-to-treat basis using a multivariate mixed-effect linear regression model. This study adheres to the Declaration of Helsinki. This study was approved by the Southern Adelaide Clinical Human Research Ethics Committee (approval number: 2022/SSA00695/OFR: 219.22, protocol version 3.3 19 February 2024). The results will be disseminated in peer-reviewed journals, conference presentations, and media.